StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.63−0.01 (-1.39%)

Close on Nov 17, 2026Market cap $59.90MP/E –Yield –

Cognition Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Cognition Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $26.14M, down 37.5% year over year. For fiscal 2025 it was $37.19M, down 10.8% from the year before. The highest annual figure on record is $41.68M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$37.19M-10.8%
FY2024Dec 31, 2024$41.68M+12.0%
FY2023Dec 31, 2023$37.20M+22.7%
FY2022Dec 31, 2022$30.32M+63.3%
FY2021Dec 31, 2021$18.57M+44.1%
FY2020Dec 31, 2020$12.89M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.10M-55.6%
Q1 FY2026Mar 31, 2026$6.12M-43.3%
Q4 FY2025Dec 31, 2025$11.15M+36.7%
Q3 FY2025Sep 30, 2025$3.77M-66.9%
Q2 FY2025Jun 30, 2025$11.48M-0.8%
Q1 FY2025Mar 31, 2025$10.79M+2.2%
Q4 FY2024Dec 31, 2024$8.15M-29.7%
Q3 FY2024Sep 30, 2024$11.39M-2.4%
Q2 FY2024Jun 30, 2024$11.58M+36.2%
Q1 FY2024Mar 31, 2024$10.55M+94.3%
Q4 FY2023Dec 31, 2023$11.60M+80.1%
Q3 FY2023Sep 30, 2023$11.67M+41.1%
Q2 FY2023Jun 30, 2023$8.50M-6.6%
Q1 FY2023Mar 31, 2023$5.43M-16.7%
Q4 FY2022Dec 31, 2022$6.44M+15.6%
Q3 FY2022Sep 30, 2022$8.27M+125.0%
Q2 FY2022Jun 30, 2022$9.10M+85.9%
Q1 FY2022Mar 31, 2022$6.52M+47.1%
Q4 FY2021Dec 31, 2021$5.57M+69.5%
Q3 FY2021Sep 30, 2021$3.68M+8.1%
Q2 FY2021Jun 30, 2021$4.89M–
Q1 FY2021Mar 31, 2021$4.43M–
Q4 FY2020Dec 31, 2020$3.29M–
Q3 FY2020Sep 30, 2020$3.40M–

More Cognition Therapeutics figures

See a number that looks wrong?